# OnCo record orm-1153 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/orm-1153/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "orm-1153" ;
  schema:name "ORM-1153"@en ;
  schema:description "ORM-1153 is an experimental degrader-antibody conjugate from Orum Therapeutics, in phase 1 trials for CD123-positive acute myeloid leukaemia."@en ;
  schema:url <https://onco.cc/drugs/orm-1153/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.orumrx.com/news/orum-therapeutics-doses-fir-phase-1-trial-of-orm-1153-a-cd123-gspt1-degrader-antibody-conjugatest-patient-in>, <https://www.orumrx.com/news/orum-therapeutics-doses-fir-phase-1-trial-of-orm-1153-a-cd123-gspt1-degrader-antibody-conjugatest-patient-in>, <https://clinicaltrials.gov/study/NCT07809906>, <https://clinicaltrials.gov/search?intr=ORM-1153> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Degrader-antibody conjugate" ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:targets <https://onco.cc/targets/cd123/> ;
  onco:companies <https://onco.cc/companies/orum-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct07809906/> .